Fingerprint
Dive into the research topics of 'Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically